Shanghai INT Medical Instruments Eyes Majority Stake in Vascular Interventional Medical Device Firm

MT Newswires Live12-18

Shanghai INT Medical Instruments (HKG:1501) is proposing to acquire a controlling stake of at least 51% in Hangzhou Weiqiang Medical Technology, a Wednesday bourse filing said.

The purchase will be executed through a capital injection of at least 200 million yuan and the acquisition of equity interest from certain shareholders of the target firm.

Following a formal agreement regarding the purchase, the capital injected into the firm will be used for working capital and repayment of bank loans and other debts.

Hangzhou Weiqiang Medical Technology mainly engages in research, development, manufacturing, and sale of aortic and peripheral vascular interventional medical devices.

Price (HKD): $27.30, Change: $+0.35, Percent Change: +1.30%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492339904?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492339904","market":"nz","top_or_hot":-1,"title":"Shanghai INT Medical Instruments Eyes Majority Stake in Vascular Interventional Medical Device Firm","media":"MT Newswires Live","content":"<html><body><p> Shanghai INT Medical Instruments (HKG:1501) is proposing to acquire a controlling stake of at least 51% in Hangzhou Weiqiang Medical Technology, a Wednesday bourse filing said.</p><p>The purchase will be executed through a capital injection of at least 200 million yuan and the acquisition of equity interest from certain shareholders of the target firm.</p><p>Following a formal agreement regarding the purchase, the capital injected into the firm will be used for working capital and repayment of bank loans and other debts.</p><p>Hangzhou Weiqiang Medical Technology mainly engages in research, development, manufacturing, and sale of aortic and peripheral vascular interventional medical devices.</p><p>Price (HKD): $27.30, Change: $+0.35, Percent Change: +1.30%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai INT Medical Instruments Eyes Majority Stake in Vascular Interventional Medical Device Firm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai INT Medical Instruments Eyes Majority Stake in Vascular Interventional Medical Device Firm\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 19:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai INT Medical Instruments (HKG:1501) is proposing to acquire a controlling stake of at least 51% in Hangzhou Weiqiang Medical Technology, a Wednesday bourse filing said.The purchase will be ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4526","symbol_name":"热门中概股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492339904","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492339904","pubTimestamp":1734521692,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai INT Medical Instruments  is proposing to acquire a controlling stake of at least 51% in Hangzhou Weiqiang Medical Technology, a Wednesday bourse filing said.The purchase will be executed through a capital injection of at least 200 million yuan and the acquisition of equity interest from certain shareholders of the target firm.Following a formal agreement regarding the purchase, the capital injected into the firm will be used for working capital and repayment of bank loans and other debts.Hangzhou Weiqiang Medical Technology mainly engages in research, development, manufacturing, and sale of aortic and peripheral vascular interventional medical devices.Price : $27.30, Change: $+0.35, Percent Change: +1.30%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4526":"热门中概股","BK4588":"碎股","BK1222":"医疗保健用品","BK4023":"应用软件","01501":"瑛泰医疗","HKD":"尚乘数科","BK4585":"ETF&股票定投概念"},"translate_title":"上海英特医疗器械收购血管介入医疗器械公司多数股权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"01501":0.9},"content_text":"Shanghai INT Medical Instruments (HKG:1501) is proposing to acquire a controlling stake of at least 51% in Hangzhou Weiqiang Medical Technology, a Wednesday bourse filing said.The purchase will be executed through a capital injection of at least 200 million yuan and the acquisition of equity interest from certain shareholders of the target firm.Following a formal agreement regarding the purchase, the capital injected into the firm will be used for working capital and repayment of bank loans and other debts.Hangzhou Weiqiang Medical Technology mainly engages in research, development, manufacturing, and sale of aortic and peripheral vascular interventional medical devices.Price (HKD): $27.30, Change: $+0.35, Percent Change: +1.30%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492339904"}